Display options
Cite
Taylor CP, Bown NP, McGuckin AG, et al. Fluorescence in situ hybridization techniques for the rapid detection of genetic prognostic factors in neuroblastoma. United Kingdom Children's Cancer Study Group. Br J Cancer. 2000;83(1):40-9doi: 10.1054/bjoc.2000.1280.
Taylor, C. P., Bown, N. P., McGuckin, A. G., Lunec, J., Malcolm, A. J., Pearson, A. D., & Sheer, D. (2000). Fluorescence in situ hybridization techniques for the rapid detection of genetic prognostic factors in neuroblastoma. United Kingdom Children's Cancer Study Group. British journal of cancer, 83(1), 40-9. https://doi.org/10.1054/bjoc.2000.1280
Taylor, C P, et al. "Fluorescence in situ hybridization techniques for the rapid detection of genetic prognostic factors in neuroblastoma. United Kingdom Children's Cancer Study Group." British journal of cancer vol. 83,1 (2000): 40-9. doi: https://doi.org/10.1054/bjoc.2000.1280
Taylor CP, Bown NP, McGuckin AG, Lunec J, Malcolm AJ, Pearson AD, Sheer D. Fluorescence in situ hybridization techniques for the rapid detection of genetic prognostic factors in neuroblastoma. United Kingdom Children's Cancer Study Group. Br J Cancer. 2000 Jul;83(1):40-9. doi: 10.1054/bjoc.2000.1280. PMID: 10883666; PMCID: PMC2374533.
Copy Download .nbib Format: NLM
Share it on

Br J Cancer. 2000 Jul;83(1):40-9. doi: 10.1054/bjoc.2000.1280.

Fluorescence in situ hybridization techniques for the rapid detection of genetic prognostic factors in neuroblastoma. United Kingdom Children's Cancer Study Group.

British journal of cancer

C P Taylor, N P Bown, A G McGuckin, J Lunec, A J Malcolm, A D Pearson, D Sheer

Affiliations

  1. Human Cytogenetics Laboratory, Imperial Cancer Research Fund, Lincoln's Inn Fields, London, UK.

PMID: 10883666 PMCID: PMC2374533 DOI: 10.1054/bjoc.2000.1280

Abstract

Neuroblastoma is the commonest extracranial solid tumour in children. There are a number of molecular genetic features known which are of prognostic importance and which are used to direct therapy. Identification and targeting of high-risk individuals with intensive therapeutic regimens may allow an improvement in survival rates. The most powerful biological parameters associated with prognosis in this malignancy are chromosomal changes, especially MYCN amplification, deletion of chromosome 1p and aneuploidy. Rapid characterization of these aberrations at the time of diagnosis is paramount if stratification according to risk group is to be achieved. This paper describes the rapid detection of del(1p), MYCN amplification and trisomy using interphase fluorescence in situ hybridization on imprints from fresh tumour biopsies. The results are related to those obtained by standard molecular methods and karyotyping.

References

  1. Nucleic Acids Res. 1979 Jul 25;6(10):3177-97 - PubMed
  2. Int J Cancer. 1992 Oct 21;52(4):544-8 - PubMed
  3. Genes Chromosomes Cancer. 1993 Jan;6(1):1-9 - PubMed
  4. Am J Pathol. 1993 May;142(5):1339-46 - PubMed
  5. Genes Chromosomes Cancer. 1993 Jun;7(2):102-8 - PubMed
  6. J Clin Oncol. 1993 Aug;11(8):1466-77 - PubMed
  7. Nat Genet. 1993 Jun;4(2):187-90 - PubMed
  8. Diagn Mol Pathol. 1992 Dec;1(4):229-34 - PubMed
  9. Br J Cancer. 1994 Mar;69(3):445-51 - PubMed
  10. Genes Chromosomes Cancer. 1994 May;10(1):30-9 - PubMed
  11. Genes Chromosomes Cancer. 1994 Aug;10(4):275-81 - PubMed
  12. Int J Cancer. 1995 Apr 10;61(2):185-91 - PubMed
  13. Eur J Cancer. 1995;31A(4):510-5 - PubMed
  14. N Engl J Med. 1996 Jan 25;334(4):225-30 - PubMed
  15. Cancer. 1995 Apr 1;75(7):1694-9 - PubMed
  16. Genes Chromosomes Cancer. 1996 Nov;17(3):156-65 - PubMed
  17. Neoplasma. 1996;43(5):301-3 - PubMed
  18. Nature. 1984 Mar 15-21;308(5956):288-91 - PubMed
  19. Science. 1984 Jun 8;224(4653):1121-4 - PubMed
  20. N Engl J Med. 1984 Jul 26;311(4):231-5 - PubMed
  21. J Natl Cancer Inst. 1984 Aug;73(2):405-16 - PubMed
  22. Genes Chromosomes Cancer. 1997 Mar;18(3):162-9 - PubMed
  23. Eur J Cancer. 1997 Oct;33(12):1917-22 - PubMed
  24. Eur J Cancer. 1997 Oct;33(12):2113-6 - PubMed
  25. N Engl J Med. 1999 Jun 24;340(25):1954-61 - PubMed
  26. N Engl J Med. 1985 Oct 31;313(18):1111-6 - PubMed
  27. Proc Natl Acad Sci U S A. 1986 May;83(9):2934-8 - PubMed
  28. Cancer. 1986 Dec 1;58(11):2453-8 - PubMed
  29. Cancer. 1987 Jun 1;59(11):1853-9 - PubMed
  30. Cancer. 1987 Aug 15;60(4):820-6 - PubMed
  31. Br J Cancer. 1988 Jan;57(1):121-6 - PubMed
  32. Cancer. 1988 Aug 15;62(4):749-54 - PubMed
  33. Cancer. 1988 Aug 15;62(4):772-80 - PubMed
  34. Cancer. 1989 Jan 1;63(1):126-32 - PubMed
  35. Proc Natl Acad Sci U S A. 1989 May;86(10):3753-7 - PubMed
  36. Cancer Genet Cytogenet. 1989 Sep;41(2):153-74 - PubMed
  37. Cancer. 1990 Mar 15;65(6):1360-6 - PubMed
  38. Genes Chromosomes Cancer. 1989 Nov;1(2):159-66 - PubMed
  39. J Clin Oncol. 1991 Apr;9(4):581-91 - PubMed
  40. J Clin Oncol. 1991 Aug;9(8):1371-5 - PubMed
  41. Cancer Res. 1992 Apr 1;52(7):1780-5 - PubMed
  42. Oncogene. 1992 Jun;7(6):1185-9 - PubMed
  43. Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321-5 - PubMed
  44. Genes Chromosomes Cancer. 1992 Sep;5(2):141-9 - PubMed
  45. Nature. 1983 Sep 15-21;305(5931):245-8 - PubMed

MeSH terms

Publication Types

Grant support